OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI ...
Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...
Cathie Wood and her Ark Invest funds sold Oklo — the nuclear power startup backed by OpenAI head Sam Altman — and purchased ...
OpenAI is putting its focus on AI infrastructure with Stargate at a time when rivals like China's DeepSeek are closing the ...
Sam Altman has told OpenAI fans to lower their expectations after rumors the company had achieved AGI went viral on X.
OpenAI announced that it is launching a research preview of Operator, an AI agent that can take control of a browser and perform tasks.
Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials this year ...